Clinical Trial

A Trial of HRS-5965 Capsule in Primary IgA Nephropathy

Name: A Trial of HRS-5965 Capsule in Primary IgA Nephropathy — clinical trial record (NCT07014826)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This multicenter, randomized, double-blind, parallel, placebo-controlled study is being conducted to evaluate the efficacy, and safety of HRS-5965 capsule for primary IgA nephropathy.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-06-03.

Status change: Not Yet Recruiting → Recruiting 2025-07-31

Trial Details

NCT Number	NCT07014826
Lead Sponsor	Chengdu Suncadia Medicine Co., Ltd.
Conditions	Primary IgA Nephropathy
Enrollment	378 participants
Start Date	2025-06-04
Primary Completion	2027-10 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2025-08-05